CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 5 enrolled
Drug / intervention
MEDI-507 +7 morebiological
Likely dose
MEDI-507 0.1 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00801632
NCT00801632Phase 2Completed

Renal Allograft Tolerance Through Mixed Chimerism

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Dec 3, 2008·Updated Nov 10, 2015

In Brief

A Phase 2 clinical trial evaluating Kidney Transplantation, Bone marrow transplantation, and 6 other interventions for Kidney Transplantation and Kidney Failure, Chronic. Completed, enrolled 5 participants across 1 site.

Detailed Summary

In small initial studies, combined kidney and bone marrow transplants from the same donor have permitted some individuals to stop taking anti-rejection medicines without rejecting their transplant. This clinical trial will study this method in a greater number of people to determine if it is indeed effective and safe.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 3, 2008
Enrollment StartDec 1, 2008
Primary CompletionApr 1, 2014
Study CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 17.6 years ago

Interventions

Kidney Transplantationprocedure

Surgical transplantation of donor kidney

Bone marrow transplantationprocedure

During kidney transplant, bone marrow cells donated by the same donor as the kidney are given through a plastic tube placed in a vein in the chest, underneath the collarbone

MEDI-507biological

0.1 mg/kg on day -2; 0.6 mg/kg on days -1,0,1

cyclophosphamidedrug

60 mg/kg infusion on days -5, -4

rituximabbiological

375 mg/m\^2 infusion on days -7, -2, 5, and 12

Tacrolimusdrug

0.05 mg/kg intravenously twice daily starting on day -1, adjusted to trough level of 10-15ng/ml, then tapered (if eligible) on days 1, 7, 14, 21, 28, 42, and 56

corticosteroidsdrug

2 mg/kg prednisone on day 4, with an additional 500-mg pulse of methylprednisolone given on days 10, 11, and 12, and then tapered off by day 20

thymic irradiationradiation

700 cGy of thymic irradiation administered in a single dose on day -1